Vascular Interventional Advances (VIVA)

Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular events, including strokes, heart attacks and blood clots, according to a study published in the American Heart Association’s journal Circulation.

Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE) approval for an Early Feasibility Study of the Tria surgical aortic heart valve to treat aortic valve disease.

Philips announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of surgeries including orthopedic, trauma and vascular procedures. The Zenition mobile C-arm platform brings together innovations in image capture, image processing, ease-of-use and versatility pioneered on Philips’ Azurion platform. Zenition allows hospitals to maximize OR performance, enhance their clinical capabilities and offer their staff a high-quality user experience. Zenition will be introduced in the U.S., Germany, Austria and Switzerland in the first half of 2019, and will subsequently be rolled out in further markets.

Epsilon Imaging recently launched the new EchoInsight Pro Starter configuration for those programs that may be budget constrained or just getting started with the incorporation of strain imaging into echo studies. The EchoInsight Pro Starter configuration starts with a two-seat bundle at an affordable, discounted package price, and can scale to up to six client seats.

IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing powerful predictive models that will enable clinicians to identify patients at serious risk for cardiovascular disease. This three-year project will incorporate population- and hospital-based biobank data, genomic information, and electronic health records to build upon and expand the predictive power of polygenic scoring. The project will also plan to make insights and tools widely available to the research community, including methods to calculate an individual’s risk of developing common diseases based on millions of variants in the genome.

Corindus Vascular Robotics Inc. is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. CorPath GRX, the second-generation robotic platform, received FDA clearance for percutaneous coronary intervention (PCI) in 2016 and peripheral vascular intervention (PVI) in 2018. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).

Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through 2028 due to the high prevalence of abdominal aortic aneurysms (AAA) relative to thoracic abdominal aneurysms (TAA), according to a new report from GlobalData. The abdominal segment will reach an estimated $2.8 billion global value by 2028, while the overall global aortic stent graft market is expected to reach $4.5 billion in the same period. This represents a compound annual growth rate of 5.4 percent between 2018 and 2028.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now